术前血清人附睾蛋白4水平与上皮性卵巢癌复发风险的关系
| 作者: |
1朱丽君,
2侯义福,
3陈传平
1 六安市中医院检验科，安徽 六安 237100 2 六安市中医院生殖中心，安徽 六安 237100 3 六安市皖西卫生职业学院，安徽 六安 237100 |
| 通讯: |
朱丽君
Email: 381938776@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2022.05.021 |
摘要
目的：探讨术前血清人附睾蛋白4(human epididymal protein 4，HE4)水平与上皮性卵巢癌(epithelial ovarian cancer，EOC)复发风险的关系。方法：回顾性分析2018年8月至2021年7月在六安市中医院接受手术综合治疗并已完成18个月随访的84例EOC患者相关资料，依据随访复发情况，分成复发组(n=31)与无复发组(n=53)。比较2组术前HE4水平、临床与病理相关资料，分析EOC复发的危险因素，并绘制受试者工作特征(receiver operating characteristic，ROC)曲线分析术前HE4水平对EOC复发的预测价值。结果：2组在FIGO分期、病理分级、淋巴结转移方面比较，差异有统计学意义(P<0.05)，复发组术前血清HE4、糖类抗原125(carbohydrate antigen 125，CA125)水平均高于无复发组(P<0.05)，且血清HE4、CA125呈正相关(r=0.604，P<0.05)。多因素logistic回归分析显示：术前血清HE4(OR=3.047，95%CI：1.924~7.125)、CA125(OR=2.392，95%CI：1.604~4.038)是EOC复发的独立影响因素(P<0.05)。ROC曲线显示：术前血清HE4、CA125预测EOC复发的曲线下面积(area under the curve，AUC)分别为0.768(95%CI：0.638~0.898)、0.748(95%CI：0.619~0.879)，二者比较无明显差异(P>0.05)，其中术前血清HE4预测EOC复发的敏感度为70.97%，特异度为75.47%。结论：术前高血清HE4水平的EOC患者可能面临更高的复发风险，术前血清HE4水平检测对EOC复发有一定预测价值。
关键词：
上皮性卵巢癌；复发；人附睾蛋白4；糖类抗原125；预测价值
Relationship between preoperative serum human epididymal protein 4 level and recurrence risk of epithelial ovarian cancer
CorrespondingAuthor: ZHU Lijun Email: 381938776@qq.com
DOI: 10.3978/j.issn.2095-6959.2022.05.021
Abstract
Objective: To investigate the relationship between preoperative serum human epididymal protein 4 (HE4) and the risk of recurrence of epithelial ovarian cancer (EOC). Methods: The data of 84 patients with EOC who received comprehensive surgical treatment in Lu’an Hospital of Traditional Chinese Medicine from August 2018 to July 2021 and have completed 18 months of follow-up were analyzed retrospectively. According to the follow-up recurrence, they were divided into the recurrence group (n=31) and the non-recurrence group (n=53). The preoperative HE4 level, clinical and pathological data of the two groups were compared; the risk factors of EOC recurrence were analyzed, and the receiver operating characteristic (ROC) curve was drawn to analyze the predictive value of preoperative HE4 level on EOC recurrence. Results: There were significant differences in FIGO stage, pathological grade and lymph node metastasis between recurrence group and non-recurrence group (P<0.05). The levels of preoperative serum HE4 and carbohydrate antigen 125 (CA125) in the recurrence group were higher than those in the non-recurrence group (P<0.05), and there was a positive correlation between serum HE4 and CA125 (r=0.604, P<0.05), and there was a positive correlation between them (r=0.604, P<0.05). Multivariate logistic regression analysis showed that preoperative serum HE4 (OR=3.047, 95%CI: 1.924–7.125) and CA125 (OR=2.392, 95%CI: 1.604–4.038) were independent factors affecting the recurrence of EOC (P<0.05). ROC curve showed that the area under curve (AUC) of preoperative serum HE4 and CA125 in predicting EOC recurrence were 0.768 (95%CI: 0.638–0.898) and 0.748 (95%CI: 0.619–0.879), respectively. There was no significant difference between them (P>0.05). The sensitivity and specificity of preoperative serum HE4 in predicting EOC recurrence were 70.97% and 75.47%. Conclusion: EOC patients with high preoperative serum HE4 level may face a higher risk of recurrence. Preoperative serum HE4 level has a certain predictive value for the recurrence of EOC.
Keywords：
epithelial ovarian cancer; recurrence; human epididymal protein 4; carbohydrate antigen 125; predictive value